Evidence map›Paper›PMID 27606888›Full record

ArticleDiabetes/metabolism research and reviews2017

A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin.

Denis Raccah, Engels Chou, Stephen Colagiuri, Zsolt Gaàl, Fernando Lavalle, Ashot Mkrtumyan, Elena Nikonova, Nikolaos Tentolouris, Josep Vidal, Melanie Davies

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes/metabolism research and reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. A Safe and Simple Algorithm for Adding and Adjusting Mealtime Insulin to Basal-Only Therapy.Clinical diabetes : a publication of the American Diabetes Association · 2022
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Denis RaccahDepartment of Diabetology, University Hospital Sainte-Marguerite, Marseille, France.
Engels ChouSanofi R&D, Bridgewater, NJ, USA.
Stephen ColagiuriBoden Institute, University of Sydney, Camperdown, NSW, Australia.
Zsolt GaàlDepartment of Medicine, András Jósa Teaching Hospital, Nyíregyháza, Hungary.
Fernando LavalleServicio de Endocrinología, Facultad de Medicina UANL, Hospital Universitario, Monterrey, NL, Mexico.
Ashot MkrtumyanMoscow State Medical and Stomatological University named after Evdokimov, Moscow, Russian Federation.
Elena NikonovaSanofi Global Medical Affairs, Bridgewater, NJ, USA.
Nikolaos TentolourisUniversity of Athens Medical School, Athens, Greece.
Josep VidalEndocrinology and Nutrition Department, Hospital Clinic, Barcelona, Spain.
Melanie DaviesDiabetes Research Centre, University of Leicester, Leicester, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study used data from different sources to identify the extent of the unmet need for postprandial glycemic control in patients with type 2 diabetes mellitus (T2DM) after the initiation of basal insulin therapy in Europe, Asia Pacific, the United States, and Latin America.

methodsDifferent levels of evidence were used as available for each country/region, with data extracted from seven randomized controlled trials (RCTs), three clinical trial registries (CTRs), and three electronic medical record (EMR) databases. Glycemic status was categorized as "well controlled" (glycated hemoglobin [HbA

resultsRCT data showed that 16.9% to 28.0%, 42.7% to 54.4%, and 16.9% to 38.1% of patients with T2DM had well-controlled glycemia, residual hyperglycemia, and uncontrolled hyperglycemia, respectively. In CTRs, respective ranges were 21.8% to 33.6%, 31.5% to 35.6%, and 30.7% to 46.8%, and in EMR databases were 4.4% to 21.0%, 23.9% to 31.8%, and 53.6% to 63.8%. Significant predictor factors of residual hyperglycemia identified from RCT data included high baseline HbA

conclusionsIrrespective of intrinsic differences between data sources, 24% to 54% of patients with T2DM globally had residual hyperglycemia with HbA

Indexed as

Needs AssessmentBiomarkersBlood GlucoseDiabetes Mellitus, Type 2FastingGlobal HealthGlycated HemoglobinHumansHyperglycemiaHypoglycemic AgentsInsulinPrognosisBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulinfasting plasma glucoseglycemic controlinsulin therapypostprandial glucoseresidual hyperglycemiatype 2 diabetes mellitus

Identifiers

PMID27606888
PMCPMC5347910

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.